Logo

Aclara and Amersham Biosciences in Marketing Collaboration

Apr 02, 2003

NEW YORK, April 2 -- Aclara BioSciences and Amersham Biosciences today announced a joint marketing agreement for DNA analysis equipment and chemistries.

 

Financial details were not provided.

 

The non-exclusive agreement joins Amersham Biosciences MegaBace DNA analysis system, and Alcara's eTag assay system, as complementary systems. The companies will continue to sell and support the systems independently, but will promote the other's products for their respective platforms.

Breaking News
The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.